Biosketch Ana Oaknin

Biosketch Ana Oaknin
Ana Oaknin
aoaknin@vhio.net
Puesto actual
  • 2009 – actualidad Jefa de grupo, Grupo de Neoplasias Ginecológicas del VHIO.
  • 2009 – actualidad Jefa de la Unidad de Tumores Ginecológicos del Departamento de Oncología Médica del Hospital Universitario Vall d’Hebron (HUVH).
  • 2017 – actualidad Mentora de los médicos internos residentes
Honores y membresías

Contribuciones científicas:

Consejos editoriales:

  • International Journal of Gynecological Cancer (revista internacional de cáncer ginecológico).
  • Miembro del consejo editorial de la revista Clínica e Investigación en Ginecología y Obstetricia.

Comité Independiente de Monitorización de Datos (IDMC)

EUDARIO: ensayo europeo sobre la inhibición mejorada de la reparación del ADN en el cáncer de ovario

ATARI: inhibidor de ATr en combinación con olaparib en cánceres ginecológicos con o sin pérdida de ARId1A

NSGO: revisión paraguas

PEACOCC: pembrolizumab en pacientes con cáncer ginecológico avanzado de células claras

Formación académica
  • 1994 Licenciatura en Medicina y Cirugía. Universidad Complutense de Madrid. España
  • 2000 Certificado de la Junta de Oncología Médica. Junta Española de Oncología Médica. Hospital Universitario de la Princesa. Universidad Complutense de Madrid.
  • 2016 Doctorado cum laude. Título de la tesis: “Mutaciones oncogénicas en cáncer de cérvix localmente avanzado: Implicaciones pronósticas y potencialmente terapéuticas”. Universidad Autónoma de Barcelona. Barcelona
  • 2018 Programa de gestión sanitaria de la inmunooncología. IESE Business School. Madrid
Premios y reconocimientos
  • Investigadora principal del ensayo clínico GARNET. Con el respaldo de los resultados preliminares* del estudio multicéntrico de fase I GARNET, en curso, que muestran la promesa de una nueva terapia inmunológica, dostarlimab, para el tratamiento más eficaz de las pacientes con cáncer de endometrio recurrente o avanzado con deficiencia de reparación de emparejamientos (dMMR/MSI-H), esta nueva inmunoterapia anti-PD-1 es la primera que ha recibido la aprobación de la Agencia Europea del Medicamento (EMA) para el tratamiento de esta población de pacientes.
  • Codirigió en nombre de ENGOT el ensayo internacional multicéntrico de fase III EMPOWER de la Fundación GOG y ENGOT, que ha demostrado la eficacia del inhibidor de PD-1, cemiplimab, como monoterapia en comparación con la quimioterapia elegida por el médico para mejorar los resultados clínicos, medidos por la supervivencia global (SG) como criterio de valoración principal.
Áreas de investigación

Mi investigación ha hecho hincapié en los esfuerzos traslacionales, principalmente en los tumores ginecológicos. Este trabajo ha abarcado objetivos de investigación preclínica y clínica, con el objetivo general de comprender la biología molecular de la enfermedad, los mecanismos de resistencia primaria y adquirida a los tratamientos y la clasificación molecular y las vulnerabilidades, con un enfoque preferente en el cáncer de ovario, cuello uterino y útero.

Investigación clínica:

Como jefa de la Unidad de Oncología Ginecológica, uno de mis objetivos principales es organizar y dirigir un plan estratégico de investigación clínica y ensayos clínicos. En la Unidad de Oncología Ginecológica nuestras pacientes son incluidas en ensayos clínicos dedicados a neoplasias específicas, como el cáncer de ovario, cérvix y útero, con el objetivo de demostrar mejoras en el mejor manejo (ensayos clínicos de fase II y fase III). He participado y contribuido en el diseño de muchos ensayos clínicos, incluidos los iniciados por investigadores, otros desarrollados en el contexto de grupos cooperativos nacionales e internacionales y algunos patrocinados directamente por empresas farmacéuticas.

Investigación traslacional en colaboración con los laboratorios genómicos del VHIO, así como con otros grupos de investigación internacionales.

Dr. Vergote del Hospital de Lovaina, Universidad Católica de Lovaina, Bélgica; Dr. Bustelo del Centro de Investigación del Cáncer (Universidad de Salamanca-CSIC); Dr. Seoane del Laboratorio de Expresión Génica y Cáncer (VHIO)

Publicaciones científicas más relevantes
  • Oaknin A, Pothuri B, Gilbert L, Sabatier R, Brown J, Ghamande S, Mathews C, O’Malley DM, Kristeleit R, Boni V, Gravina A, Banerjee S, Miller R, Pikiel J, Mirza MR, Dewal N, Antony G, Dong Y, Zografos E, Veneris J, Tinker AV. Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study. Clin Cancer Res. 2023 Nov 14;29(22):4564-4574.
  • DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, McNamara J, Lowe ES, Ah-See ML, Moore KN; SOLO1 Investigators. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. J Clin Oncol. 2023 Jan 20;41(3):609-617.
  • Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, Denys H, Rosengarten O, Rodrigues M, de Gregorio N, Martinez García J, Petru E, Kocián R, Vergote I, Pautier P, Schmalfeldt B, Gaba L, Polterauer S, Mouret Reynier MA, Sehouli J, Churruca C, Selle F, Joly F, D’Hondt V, Bultot-Boissier É, Lebreton C, Lotz JP, Largillier R, Heudel PE, Heitz F; ATALANTE/ENGOT-ov29 Investigators. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial. J Clin Oncol. 2023 Oct 20;41(30):4768-4778.
  • González-Martín A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, Ray-Coquard I, Tan DSP, Bellet E, Oaknin A, Ledermann JA; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Oct;34(10):833-848.
  • Kristeleit R, Lisyanskaya A, Fedenko A, Dvorkin M, de Melo AC, Shparyk Y, Rakhmatullina I, Bondarenko I, Colombo N, Svintsitskiy V, Biela L, Nechaeva M, Lorusso D, Scambia G, Cibula D, Póka R, Oaknin A, Safra T, Mackowiak-Matejczyk B, Ma L, Thomas D, Lin KK, McLachlan K, Goble S, Oza AM. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2022 Apr;23(4):465-478.
  • Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Survival with Cemiplimab in Recurrent Cervical Cancer. N Engl J Med. 2022 Feb 10;386(6):544-555.
  • Oaknin A, Monk BJ, Vergote I, Cristina de Melo A, Kim YM, Lisyanskaya AS, Samouëlian V, Kim HS, Gotovkin EA, Damian F, Chang CL, Takahashi S, Li J, Mathias M, Fury MG, Ivanescu C, Reaney M, LaFontaine PR, Lowy I, Harnett J, Chen CI, Tewari KS. EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer. Eur J Cancer. 2022 Oct;174:299-309.
  • Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, Sabatier R, O’Malley DM, Samouelian V, Boni V, Duska L, Ghamande S, Ghatage P, Kristeleit R, Leath C III, Guo W, Im E, Zildjian S, Han X, Duan T, Veneris J, Pothuri B. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer. 2022 Jan;10(1):e003777.
  • Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, Oaknin A. Endometrial cancer. Nat Rev Dis Primers. 2021 Dec 9;7(1):88. doi: 10.1038/s41572-021-00324-8. PMID: 34887451.
  • Liu J, Oza AM, Colombo N, Oaknin A. ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma. Int J Gynecol Cancer. 2022 Jan;32(1):89-92. doi: 10.1136/ijgc-2021-003144. Epub 2021 Oct 29. PMID: 34716177.
  • Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley WH, Holmes E, Lowe ES, DiSilvestro P. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 Dec;22(12):1721-1731. doi: 10.1016/S1470-2045(21)00531-3. Epub 2021 Oct 26. Erratum in: Lancet Oncol. 2021 Dec;22(12):e539. PMID: 34715071.
  • Oaknin A, Oza AM, Lorusso D, Aghajanian C, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Amenedo Gancedo M, Fong PC, Goh JC, O’Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Ledermann JA, Coleman RL. Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. Cancer Med. 2021 Oct;10(20):7162-7173. doi: 10.1002/cam4.4260. Epub 2021 Sep 21. PMID: 34549539; PMCID: PMC8525125.
  • Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, Barretina-Ginesta MP, Moreno V, Gravina A, Abdeddaim C, Banerjee S, Guo W, Danaee H, Im E, Sabatier R. Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer. Future Oncol. 2021 Oct 1;17(29):3781-3785. doi: 10.2217/fon-2021-0598. Epub 2021 Aug 24. PMID: 34427115.
  • Romero OA, Vilarrubi A, Alburquerque-Bejar JJ, Gomez A, Andrades A, Trastulli D, Pros E, Setien F, Verdura S, Farré L, Martín-Tejera JF, Llabata P, Oaknin A, Saigi M, Piulats JM, Matias-Guiu X, Medina PP, Vidal A, Villanueva A, Sanchez-Cespedes M. SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade. Nat Commun. 2021 Jul 14;12(1):4319. doi: 10.1038/s41467-021-24618-3. PMID: 34262032; PMCID: PMC8280185.
  • Swisher EM, Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Aghajanian C, Konecny GE, O’Malley DM, Leary A, Provencher D, Welch S, Chen LM, Wahner Hendrickson AE, Ma L, Ghatage P, Kristeleit RS, Dorigo O, Musafer A, Kaufmann SH, Elvin JA, Lin DI, Chambers SK, Dominy E, Vo LT, Goble S, Maloney L, Giordano H, Harding T, Dobrovic A, Scott CL, Lin KK, McNeish IA. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat Commun. 2021 May 3;12(1):2487. doi: 10.1038/s41467-021-22582-6. PMID: 33941784; PMCID: PMC8093258.
  • Friedlander M, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Lisyanskaya A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Liu J, Mathews C, Selle F, Lortholary A, Lowe ES, Hettle R, Flood E, Parkhomenko E, DiSilvestro P. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. Lancet Oncol. 2021 May;22(5):632-642. doi: 10.1016/S1470-2045(21)00098-X. Epub 2021 Apr 13. PMID: 33862001.
  • Perez-Fidalgo JA, Grau F, Fariñas L, Oaknin A. Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicine. Crit Rev Oncol Hematol. 2021 Feb;158:103209. doi: 10.1016/j.critrevonc.2020.103209. Epub 2020 Dec 31. PMID: 33388455.
  • Redondo A, Oaknin A, Rubio MJ, Barretina-Ginesta MP, de Juan A, Manso L, Romero I, Martin-Lorente C, Poveda A, Gonzalez-Martin A. Management of advanced ovarian cancer in Spain: an expert Delphi consensus. J Ovarian Res. 2021 May 26;14(1):72. doi: 10.1186/s13048-021-00816-x.
  • Swisher EM, Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Aghajanian C, Konecny GE, O’Malley DM, Leary A, Provencher D, Welch S, Chen LM, Wahner Hendrickson AE, Ma L, Ghatage P, Kristeleit RS, Dorigo O, Musafer A, Kaufmann SH, Elvin JA, Lin DI, Chambers SK, Dominy E, Vo LT, Goble S, Maloney L, Giordano H, Harding T, Dobrovic A, Scott CL, Lin KK, McNeish IA. Share Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat Commun. 2021 May 3;12(1):2487. doi: 10.1038/s41467-021-22582-6.
  • Friedlander M, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Lisyanskaya A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Liu J, Mathews C, Selle F, Lortholary A, Lowe ES, Hettle R, Flood E, Parkhomenko E, DiSilvestro P. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. Lancet Oncol. 2021 May;22(5):632-642. doi: 10.1016/S1470-2045(21)00098-X. Epub 2021 Apr 13.
  • Konecny GE, Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, Ray-Coquard I, Aghajanian C, Coleman RL, O’Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Castro C, Green M, Simmons AD, Beltman J, Harding T, Lin KK, Goble S, Maloney L, Kristeleit RS, McNeish IA, Swisher EM, Xiao JJ. Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. Gynecol Oncol. 2021 Jun;161(3):668-675. doi: 10.1016/j.ygyno.2021.03.015. Epub 2021 Mar 19.
  • Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, Konecny GE, Banerjee S, Murphy CG, Tanyi JL, Hirte H, Konner JA, Lim PC, Prasad-Hayes M, Monk BJ, Pautier P, Wang J, Berkenblit A, Vergote I, Birrer MJ. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARDI.IAnn Oncol. 2021 Mar 2:S0923-7534(21)00157-5. doi: 10.1016/j.annonc.2021.02.017.
  • Poveda A, Oaknin A, Romero I, Guerrero-Zotano A, Fariñas-Madrid L, Rodriguez-Freixinos V, Mallol P, Lopez-Reig R, Lopez-Guerrero JA. A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors. Sci Rep. 2021 Feb 24;11(1):4433. doi: 10.1038/s41598-021-82671-w.
  • Ligero M, Garcia-Ruiz A, Viaplana C, Villacampa G, Raciti MV, Landa J, Matos I, Martin-Liberal J, Ochoa-de-Olza M, Hierro C, Mateo J, Gonzalez M, Morales-Barrera R, Suarez C, Rodon J, Elez E, Braña I, Muñoz-Couselo E, Oaknin A, Fasani R, Nuciforo P, Gil D, Rubio-Perez C, Seoane J, Felip E, Escobar M, Tabernero J, Carles J, Dienstmann R, Garralda E, Perez-Lopez R. A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Radiology . 2021 Jan 26;200928. doi: 10.1148/radiol.2021200928.
  • Perez-Fidalgo JA, Grau F, Fariñas L, Oaknin A. Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicine Crit Rev Oncol Hematol. 2020 Dec 31:103209. doi: 10.1016/j.critrevonc.2020.103209
  • Lorusso D, Ray-Coquard I, Oaknin A, Banerjee S. Clinical research disruption in the post-COVID-19 era: will the pandemic lead to change? ESMO Open. 2020 Oct;5(5):e000924. doi: 10.1136/esmoopen-2020-000924.
  • Colombo N, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O’Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Meunier J, Cameron T, Maloney L, Goble S, Bedel J, Ledermann JA, Coleman RL. The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma Gynecol Oncol. 2020 Oct;159(1):101-111. doi: 10.1016/j.ygyno.2020.05.045.
  • Krishnansu S. Tewari, Michael W Sill, Bradley J. Monk, Richard T Penson, David H Moore, Heather A Lankes, Lois M Ramondetta, Lisa M Landrum, Leslie M Randall, Ana Oaknin, Mario Leitao, Eric L Eisenhauer, Paul DiSilvestro, Linda Van Le, Michael L Pearl, James J Burke, Ritu Salani, Debra L Richardson, Helen E Michael, David W Kindelberger, and Michael J Birrer. Circulating Tumor Cells In Advanced Cervical Cancer:NRG Oncology – Gynecologic Oncology Group Study 240 (NCT 00803062) Molecular Cancer Therapeutics. 20 Aug 26:molcanther.0276.2020. doi: 10.1158/1535-7163.MCT-20-0276
  • Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O’Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cella D, Meunier J, Goble S, Cameron T, Maloney L, Mörk AC, Bedel J, Ledermann JA, Coleman RL Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma J Clin Oncol. 2020 Aug 24:JCO1903107. doi: 10.1200/JCO.19.03107
  • DiSilvestro P, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian CA, Bradley WH, Mathews CA, Liu J, Lowe ES, Bloomfield R, Moore KN. Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial J Clin Oncol. 2020 Aug 4:JCO2000799. doi: 10.1200/JCO.20.00799
  • Oaknin A, León-Castillo A, Lorusso D. Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA pathway): data and perspectives Curr Opin Oncol. 2020 Sep;32(5):471-480. doi: 10.1097/CCO.0000000000000658
  • Oaknin A, Friedman CF, Roman LD, D’Souza A, Brana I, Bidard FC, Goldman J, Alvarez EA, Boni V, ElNaggar AC, Passalacqua R, Do KTM, Santin AD, Keyvanjah K, Xu F, Eli LD, Lalani AS, Bryce RP, Hyman DM, Meric-Bernstam F, Solit DB, Monk BJ. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial Gynecol Oncol. 2020 Jul 25:S0090-8258(20)33660-X. doi: 10.1016/j.ygyno.2020.07.025
  • Lheureux S, Oaknin A, Garg S, Bruce JP, Madariaga A, Dhani NC, Bowering V, White J, Accardi S, Tan Q, Braunstein M, Karakasis K, Cirlan I, Pedersen S, Li T, Fariñas-Madrid L, Lee YC, Liu ZA, Pugh TJ, Oza AM. EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer After PARP Inhibition Progression
  • Clin Cancer Res 2020 May 22; clincanres.4121.2019. doi: 10.1158/1078-0432.CCR-19-4121.
  • Muñoz-Guardiola P, Casas J, Megías-Roda E, Solé S, Perez-Montoyo H, Yeste-Velasco M, Erazo T, Diéguez-Martínez N, Espinosa-Gil S, Muñoz-Pinedo C, Yoldi G, Abad JL, Segura MF, Moran T, Romeo M, Bosch-Barrera J, Oaknin A, Alfón J, Domènech C, Fabriàs G, Velasco G, Lizcano JM. The Anti-Cancer Drug ABTL0812 Induces ER Stress-Mediated Cytotoxic Autophagy by Increasing Dihydroceramide Levels in Cancer Cells. Autophagy 2020 May 25;1-18. doi: 10.1080/15548627.2020.1761651.
  • Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O’Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL. Rucaparib for Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (ARIEL3): Post-Progression Outcomes and Updated Safety Results From a Randomised, Placebo-Controlled, Phase 3 Trial Lancet Oncol. 2020 May;21(5):710-722. doi: 10.1016/S1470-2045(20)30061-9.
  • Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, Romeo M, Bratos R, Brose MS, DiSimone C, Messing M, Stepan DE, Dutcus CE, Wu J, Schmidt EV, Orlowski R, Sachdev P, Shumaker R, Casado Herraez A. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. J Clin Oncol. 2020 Mar 13:JCO1902627. doi: 10.1200/JCO.19.02627
  • Chase D, Huang HQ, Monk BJ, Ramondetta LM, Penson RT, Gil K, Landrum LM, Leitao M, Oaknin A, Huh WK, Pulaski HL, Robison K, Guntupalli SR, Richardson D, Salani R, Sill MW, Wenzel LB, Tewari KS. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study Int J Gynecol Cancer. 2020 Feb 28. pii: ijgc-2019-000869. doi: 10.1136/ijgc-2019-000869
  • de Juan A, Redondo A, Rubio MJ, García Y, Cueva J, Gaba L, Yubero A, Alarcón J, Maximiano C, Oaknin A. SEOM clinical guidelines for cervical cancer (2019). Clin Transl Oncol. 2020 Feb;22(2):270-278. doi: 10.1007/s12094-019-02271-z. Epub 2020 Jan 24.
  • Matos I, Martin-Liberal J, Garcia-Ruiz A, Hierro C, Ochoa de Olza M, Viaplana C, Azaro A, Vieito M, Brana I, Mur G, Ros J, Mateos J, Villacampa G, Berché R, Oliveira M, Alsina M, Élez E, Oaknin A, Muñoz-Couselo E, Carles J, Felip E, Rodon J, Tabernero J, Dienstmann R, Perez-Lopez R, Garralda E. Capturing Hyperprogressive disease with immune checkpoint inhibitors using RECIST 1.1 criteria. Clin Cancer Res. 2019 Nov 22. pii: clincanres.2226.2019. doi: 10.1158/1078-0432.CCR-19-2226
  • Rodriguez-Freixinos V, Fariñas-Madrid L, Gil-Martin M, Barretina-Ginesta P, Romeo M, Villacampa G, Pardo B, Ahmed H, Recalde S, Piulats JM, Gomez-Plaza MC, Gil-Moreno A, Sala E, Martínez-Roman S, Ponce J, Melendez C, Carballas E, Dienstmann R, Oaknin A. Corrigendum to ‘Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients’ [Gynecologic Oncology 152 (2019) 270-277]. Gynecol Oncol. 2019 Nov 16. Doi: 10.1016/j.ygyno.2019.10.020.
  • Kristeleit RS, Oaknin A, Ray-Coquard I, Leary A, Balmaña J, Drew Y, Oza AM, Shapira-Frommer R, Domchek SM, Cameron T, Maloney L, Goble S, Lorusso D, Ledermann JA, McNeish IA. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety. Int J Gynecol Cancer. 2019 Nov;29(9):1396-1404. doi: 10.1136/ijgc-2019-000623
  • Grau JF, Farinas-Madrid L, Oaknin A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030). A Int J Gynecol Cancer. 2019 Oct 23. pii: ijgc-2019-000880. doi: 10.1136/ijgc-2019-000880
  • Drew Y, Kristeleit RS, Oaknin A, Ray-Coquard I, Haris NM, Swisher EM. Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10. Oncologist. 2019 Oct 1. pii: theoncologist.2019-0229. doi: 10.1634/theoncologist.2019-0229
  • Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019 Sep 28. doi: 10.1056/NEJMoa1909707
  • Naumann RW, Hollebecque A, Meyer T, Devlin MJ, Oaknin A, Kerger J, López-Picazo JM, Machiels JP, Delord JP, Evans TRJ, Boni V, Calvo E, Topalian SL, Chen T, Soumaoro I, Li B, Gu J, Zwirtes R, Moore KN Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. J Clin Oncol. 2019 Sep 5: JCO1900739. doi: 10.1200/JCO.19.00739.
  • Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol. 2019 Jun 20. Doi: 10.1093/annonc/mdz192
  • Liu JF, Gordon M, Veneris J, Braiteh F, Balmanoukian A, Eder JP, Oaknin A, Hamilton E, Wang Y, Sarkar I, Molinero L, Fassò M, O’Hear C, Lin YG, Emens LA. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol. 2019 Jun 13. Doi: 10.1016/j.ygyno.2019.05.021.
  • Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger PB, Rudaitis V, Katchar K, Wu H, Keefe S, Ruman J, Ledermann JA. Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study.  Ann Oncol. 2019 May 2. Doi 10.1093/annonc/mdz135:
  • Rodriguez-Freixinos V, Ruiz-Pace F, Fariñas-Madrid L, Garrido-Castro AC, Villacampa G, Nuciforo P, Vivancos A, Dienstmann R, Oaknin A. Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. ESMO Open. 2019 Mar 8
  • Felip I, Moiola CP, Megino-Luque C, Lopez-Gil C, Cabrera S, Solé-Sánchez S, Muñoz-Guardiola P, Megias-Roda E, Pérez-Montoyo H, Alfon J, Yeste-Velasco M, Santacana M, Dolcet X, Reques A, Oaknin A, Rodríguez-Freixinos V, Lizcano JM, Domènech C, Gil-Moreno A, Matias-Guiu X, Colas E, Eritja N.Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer. Gynecol Oncol. 2019 Mar 7. pii: S0090-8258(19)30150-7 DOI: 10.1016/j.ygyno.2019.03.002
  • Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019 Jan 12;393(10167):169-182. doi: 10.1016/S0140-6736(18)32470-X. Review
  • Rodriguez-Freixinos V, Fariñas-Madrid L, Gil-Martin M, Barretina-Ginesta P, Romeo M, Villacampa G, Pardo B, Ahmed H, Recalde S, Piulats JM, Gómez-Plaza MC, Gil-Moreno A, Sala E, Martínez-Román S, Ponce J, Meléndez C, Carballas E, Dientsmann R, Oaknin A. Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients. Gynecol Oncol. 2018 Dec 12. DOI: 10.1016/j.ygyno.2018.11.036
  • Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O’Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM. BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.Cancer Discov. 2018 Nov 13. DOI: 10.1158/2159-8290.CD-18-0715
  • Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.N Engl J Med. 2018 Dec 2 DOI: 10.1056/NEJMoa18108587.
  • Van Nieuwenhuysen E, Busschaert P, Neven P, Han SN, Moerman P, Liontos M, Papaspirou M, Kupryjanczyk J, Hogdall C, Hogdall E, Oaknin A, Garcia A, Mahner S, Trillsch F, Cibula D, Heitz F, Concin N, Speiser P, Salvesen H, Sehouli J, Lambrechts D, Vergote I. The genetic landscape of 87 ovarian germ cell tumors. Gynecol Oncol. 2018 Oct. DOI: 10.1016/j.ygyno.2018.08.013
  • Gil-Moreno A, Carbonell-Socias M, Salicrú S, Centeno-Mediavilla C, Franco-Camps S, Colas E, Oaknin A, Pérez-Benavente A, Díaz-Feijoo B “Radical Hysterectomy: Efficacy and Safety in the Dawn of Minimally Invasive Techniques” J Minim Invasive Gynecol. 2018 Jun 13. DOI: 10.1016/j.jmig.2018.06.007
  • Ray-Coquard I, Morice P, Lorusso D, Prat J, Oaknin A, Pautier P, Colombo N; ESMO Guidelines Committee. “Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Ann Oncol. 2018 Apr 25. DOI: 10.1093/annonc/mdy001
  • Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN, Kristel P, de Bustos L, Guzman M, Rodríguez O, Grueso J, Montalban G, Caratú G, Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O, O’Connor MJ, Balmaña J, Serra V. “RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.” Ann Oncol. 2018 May 1;29(5):1203-1210. DOI: 10.1093/annonc/mdy099
  • Oaknin A, Guarch R, Barretina P, Hardisson D, González-Martín A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios. “Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology”. Rev Esp Patol. 2018 Apr – Jun;51(2):84-96. DOI: 10.1007/s12094-017-1719-x
  • Moore KN, Vergote I, Oaknin A, Colombo N, Banerjee S, Oza A, Pautier P, Malek K, Birrer MJ. “FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.” Future Oncol. 2018 Feb 9. DOI: 10.2217/fon-2017-0646
  • Seamon LG, Java JJ, Monk BJ, Penson RT, Brown J, Mannel RS, Oaknin A, Leitao MM, Eisenhauer EL, Long HJ, Liao SY, Tewari KS. “Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study”. Br J Cancer. 2018 Jan;118(2):162-170. DOI: 10.1038/bjc.2017.400
  • Oaknin A, Guarch R, Barretina P, Hardisson D, González-Martín A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J. “Erratum to: Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.” Clin Transl Oncol. 2018 Mar;20(3):424. DOI: 10.1007/s12094-017-1746-7
  • Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O’Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators. “Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial”. Lancet. 2017 Sep 12. Doi: 10.1016/S0140-6736(17)32440-6
  • Amit M. Oza,*, Anna V. Tinker, Ana Oaknin, Ronnie Shapira-Frommerd, Iain A. McNeishe, Elizabeth M. Swisherf, Isabelle Ray-Coquardg, Katherine Bell-McGuinnh,†, Robert L. Colemani, David M. O’Malleyj, Alexandra Learyk, Lee-may Chenl, Diane Provencherm, Ling Man, James D. Brentono, Gottfried E. Konecnyp, Cesar M. Castroq, Heidi Giordanor, Lara Maloneyr, Sandra Gobler, Kevin K. Linr, James Suns, Mitch Raponir, Lindsey Rolfer, Rebecca S. Kristeleit. “Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2”. Gynecol Oncol. 2017 Sep 4. DOI: 10.1016/j.ygyno.2017.08.022
  • Oaknin A, Guarch R, Barretina P, Hardisson D, González-Martín A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J. “Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology”. Clin Transl Oncol. 2018 Mar;20(3):274-285. DOI: 10.1007/s12094-017-1719-x
  • Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ. “Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).  Lancet Oncol. 2017 Jan;18(1):75-87. DOI: 10.1016/S0140-6736(17)31607-0
  • Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O’Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA. “Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.”. Lancet Oncol. 2017 Jan;18(1):75-87. DOI: 10.1016/S1470-2045(16)30559-9
  • Pautier P1, Vergote I, Joly F, Melichar B, Kutarska E, Hall G, Lisyanskaya A, Reed N, Oaknin A, Ostapenko V, Zvirbule Z, Chetaille E, Geniaux A, Shoaib M, Green JA.A “Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer”. Int J Gynecol Cancer. 2017 Feb;27(2):258-266. DOI: 10.1097/IGC.0000000000000862
  • Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Ma H, Vogl FD, Bach BA, Oza AM. “Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2”.Gynecol Oncol. 2016 Oct;143(1):27-34. DOI: 10.1016/j.ygyno.2016.07.112
  • Fujiwara K, Monk BJ, Lhommé C, Coleman RL, Brize A, Oaknin A, Ray-Coquard I, Fabbro M, Provencher D, Bamias A, Vergote I, DeCensi A, Zhang K, Vogl FD, Bach BA, Raspagliesi F. “Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1)”. Ann. Oncol. 2016 Jun; 27(6):1006-13. DOI: 10.1093/annonc/mdw147
  • Oaknin A, Rubio MJ, Redondo A, De Juan A, Cueva Bañuelos JF, Gil-Martin M, Ortega E, Garcia-Arias A, Gonzalez-Martin A, Bover I. “SEOM guidelines for cervical cáncer”. Clin Transl Oncol. 2015 Dec;17(12):1036-42. doi: 10.1007/s12094-015-1452-2
  • McMeekin S, Dizon D, Barter J, Scambia G, Manzyuk L, Lisyanskaya A, Oaknin A, Ringuette S, Mukhopadhyay P, Rosenberg J, Vergote I. “Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer”. Gynecol Oncol. 2015 Jul;138(1):18-23. DOI: 10.1016/j.ygyno.2015.04.026
  • Penson RT, Huang HQ, Wenzel LB, Monk BJ, Stockman S, Long HJ 3rd, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Method M, Michael H, Tewari KS. “Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240”. Lancet Oncol. 2015 Mar;16(3):301-11. DOI: 10.1016/S1470-2045(15)70004-5
  • Vergote I, Oaknin A, Baurain JF, Ananda S, Wong S, Su X, Wu B, Zhong Z, Warner D, Casado A. ”A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery.” Eur J Cancer. 2014 Sep;50(14):2408-16. doi.org/10.1016/j.ejca.2014.06.010
  • Abu-Rustum N, Chi D, Coleman RL, Del Campo JM, Fotopoulou C, Frumovitz M, Gershenson DM, Gonzalez A, Jhingran A, Ledermann J, Mariani A, Mirza M, Oaknin A, Ramirez PT, Schmeler KM, Sood AK Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: Emerging therapies in gynecologic cancer. Gynecol Oncol. 2014 Jul; 134(1):6-9. DOI: 10.1016/j.ygyno.2014.04.042
  • Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM. “Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial”. Lancet Oncol. 2014 Jul; 15(8):799-808. DOI: 10.1016/S1470-2045(14)70244-X
  • Salazar R1, Morales S, Gil-Martín M, Aguirre E, Oaknin A, Garcia M, Callies S, Wickremsinhe ER, Benhadji KA, Llombart A “Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2. 334737) in combination with docetaxel in patients with advanced solid tumors”. Cancer Chemother Pharmacol. 2014 Jun;73(6):1205-15. doi: 10.1007/s00280-014-2457-1
  • Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. “Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial”. J Clin. Oncol. 2014 May 1; 32(13):1302-8.
  • Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. “Improved survival with bevacizumab in advanced cervical cancer”. N Engl J Med. 2014 Feb 20; 370(8):734-43. DOI: 10.1200/JCO.2013.51.4489
  • Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D4, Gore M5, Scambia G, Oaknin A, Sneller V8, Freudensprung U8, Pignata S9; OCTAVIA investigators. “Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer)”. Eur. J Cancer. 2014 Jan 9. DOI: 10.1016/j.ejca.2013.12.001
  • Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Kovalenko N, Oaknin A, Ronco JP, Freudensprung U, Pignata S; OCTAVIA Investigators. “Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer”. Eur. J Cancer. 2013 Dec; 49(18):3831-8. doi.org/10.1016/j.ejca.2013.08.002
  • Salazar R, Jones RJ, Oaknin A, Crawford D, Cuadra C, Hopkins C, Gil M, Coronado C, Soto-Matos A, Cullell-Young M, Iglesias Dios JL, Evans TR. “A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors. Cancer”. Chemother. Pharmacol., 2012 Nov; 70(5.) 673-81. DOI: 10.1007/s00280-012-1951-6
  • Diaz-Padilla I, Monk BJ, Mackay HJ, Oaknin A. “Treatment of metastatic cervical cancer: Future directions involving targeted agents”. Crit. Rev. Oncol. Hematol. 2013 Mar; 85(3):303-14. DOI: 10.1016/j.critrevonc.2012.07.006
  • Oaknin A,  Diaz-Corcuera I, Rodriguez- Freixinos V, Del Campo JM. “SEOM Guidelines for Cervical Cancer.” Clin. Transl. Oncol. 2012 Jul; 14(7):516-9. DOI: 10.1007/s12094-012-0834-y
  • Oaknin A, Rodriguez- Freixinos V, Diaz-Corcuera I, Del Campo JM. “SEOM Guidelines for Endometrial Cancer”. Clin. Transl. Oncol. 2012 Jul; 14(7):512-5. DOI: 10.1007/s12094-012-0833-z
  • Massard C, Salazar R, Armand JP, Majem M, Deutsch E, García M, Oaknin A, Fernández-García EM, Soto A, Soria JC. “Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors”. Invest New Drugs. 2012Dec; 30(6):2318-26. DOI: 10.1007/s10637-011-9772-8
  • Oaknin A, Roda D, González-Martín A, Chiva L, García-Donas J, de Juan A, Redondo A, Martínez S, García Y, Catot S, Ponce J, Del Campo JM, Cervantes A, Poveda A.. “Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study”. Int J Gynecol Cancer. 2011 Aug;21(6):1048-55. DOI: 10.1097/IGC.0b013e31821ee777
  • Serrano C, García Á, Brana I, Pérez-Benavente A, Oaknin A. “Angiosarcoma of the ovary: is it always a lethal disease?” 2010 Sep 7. DOI: 10.1200/JCO.2010.30.0830
  • Salazar R, Plummer R, Oaknin A, Robinson A, Pardo B, Soto-Matos A, Yovine A, Szyldergemajn S, Calvert AH. “Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas”. Invest New Drugs. 2011 Dec;29(6):1406-13. DOI: 10.1007/s10637-010-9488-1
  • Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A. “Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial”. Lancet. 2010 Jul 24;376(9737):245-51. DOI: 10.1016/S0140-6736(10)60893-8
  • Monk BJ, Mas Lopez L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, Alber JA, Ding J, Stutts MW, Pandite LN. “Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer”.J Clin Oncol. 2010 Aug 1;28(22):3562-9. DOI: 10.1200/JCO.2009.26.9571
  • Del Campo JM, Muñoz-Couselo E, Diaz de Corcuera I, Oaknin A. “Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer”. Expert Rev Anticancer Ther. 2010 Jun;10(6):795-805. DOI: 10.1586/era.10.59
  • Oaknin A, Barretina MP, Morilla I. “Muscle metastasis of low-grade endometrial carcinoma seven years after diagnosis: a case report.”. Int J Gynecol Cancer. 2010 Jan;20(1):87-91.
  • Oaknin A, Barretina P, Pérez X, Jimenez L, Velasco M, Alsina M, Brunet J, Germà JR, Beltran M. “CA-125 response patterns in patients with recurrent ovarian cancer treated with pegylated liposomal doxorubicin (PLD)”. Int J Gynecol Cancer. 2010 Jan;20(1):87-91. DOI: 10.1111/IGC.0b013e3181c16ba1
  • Oaknin A, Barretina MP. “Human papillomavirus vaccine and cervical cancer prevention”. Clin Transl Oncol. 2008 Dec;10(12):804-11. Review. DOI: 10.1007/s12094-008-0293-7
  • Poveda A, Salazar R, del Campo JM, Mendiola C, Cassinello J, Ojeda B, Arranz JA, Oaknin A, García-Foncillas J, Rubio MJ, González Martín A. “Update in the management of ovarian and cervical carcinoma”. Clin Transl Oncol. 2007 Jul;9(7):443-51. DOI: 10.1007/s12094-007-0083-7
Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.
Privacy Policy
You have read and agreed to our privacy policy
Requerido